The Channel 10 news program telecast information from the primary kidney cancer study that we had participated in. The results had shown that in the intermediate or poor risk kidney cancer patients, combination therapy with Ipilimumab and Nivolumab was much better that the standard of care tablets. Immunotherapy was better than just simple targeted therapies.
It focused on a story of a gentleman who was diagnosed with kidney cancer a few years ago and was then started on the combination immunotherapy (as part of a clinical trial). He did exceedingly well on the study and has no measurable cancer (on CT scans). He is doing well and is back to his normal routine of life.